NASDAQ: TRDA - Entrada Therapeutics, Inc.

Yield per half year: +24.36%
Dividend yield: 0.00%
Sector: Healthcare

Share chart Entrada Therapeutics, Inc.

Extended chart Simple chart
Financial Markets by TradingView

About Entrada Therapeutics, Inc.

Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs.

more details
The company's lead therapeutic candidates, which include ENTR-601-44 and ENTR-601-45, which are in preclinical trail for the treatment of Duchenne muscular dystrophy and myotonic dystrophy type 1; ENTR-501, an intracellular thymidine phosphorylase enzyme replacement therapy, which is in preclinical trail for the treatment of mitochondrial neurogastrointestinal encephalomyopathy; and ENTR-701, which is in preclinical trail for the treatment of myotonic dystrophy type 1. Entrada Therapeutics, Inc. has a strategic collaboration and license agreement with Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize ENTR-701. The company was formerly known as CycloPorters, Inc. and changed its name to Entrada Therapeutics, Inc. in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Add to compare list
Add to watchlist
Add to portfolio
Add to notification price

IPO date 2021-10-29
ISIN US29384C1080
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.entradatx.com
Цена ао 13.76
Change price per day: -1.86% (17.74)
Change price per week: -1.02% (17.59)
Change price per month: -12.2% (19.83)
Change price per 3 month: +5.84% (16.45)
Change price per half year: +24.36% (14)
Change price per year: +15.37% (15.09)
Change price per 3 year: +27.08% (13.7)
Change price per 5 year: 0% (17.41)
Change price per 10 year: 0% (17.41)
Change price per year to date: -7.39% (18.8)
All parameters

Underestimation

Title Value Grade
P/S 4.28 4
P/BV 2.28 6
P/E 0 0
EV/EBITDA -1720.37 0
Total: 5

Efficiency

Title Value Grade
ROA, % -1.42 0
ROE, % -2.76 0
Total: 0

Dividends

Title Value Grade
Div yield, % 0 0
DSI 0 0
Total: 0

Debt

Title Value Grade
Debt/EBITDA -212.55 10
Total: 10

Growth impulse

Title Value Grade
Yield Revenue, % 410.74 10
Yield Ebitda, % -97.26 0
Yield EPS, % -43.91 0
Total: 3.2
More

Institutions Volume Share, %
Baker Brothers Advisors, LLC 4865819 14.48
Mpm Asset Management, LLC 4425784 13.17
5AM Venture Management, LLC 4408379 13.12
Price (T.Rowe) Associates Inc 3009673 8.96
Blackrock Inc. 1502537 4.47
Redmile Group, LLC 1283735 3.82
Vanguard Group Inc 1065166 3.17
Wellington Management Group, LLP 1047780 3.12
StepStone Group LP 761277 2.27
Tcg Crossover Management, Llc 584955 1.74

ETF Share, % Profitability for 1 year, % Dividends, %
iShares Neuroscience and Healthcare ETF 0.59012 19.72 0.03
First Trust Dow Jones Select MicroCap Index Fund 0.52221 26.18 1.56612
iShares Micro-Cap ETF 0.09211 17.09 1.54048
WisdomTree U.S. SmallCap Fund 0.07886 15.03 1.80258
Goldman Sachs ActiveBeta US Small Cap Equity ETF 0.05026 31.36 1.41955
Avantis U.S Small Cap Equity ETF 0.04469 27.77 1.68271
Nuveen ESG Small-Cap ETF 0.02399 13.91 1.41019
Vanguard Russell 2000 ETF 0.02 17.16 1.48801
ProShares UltraPro Russell2000 0.00784 89.82 1.47873
Schwab U.S. Small-Cap ETF 0.00715 17.47 1.51433
Fidelity MSCI Health Care Index ETF 0.00401 3 1.46057
Avantis Responsible U.S. Equity ETF 0.00307 26.78 1.45257
Dimensional US Small Cap Value ETF 0.00252 25.85 1.97866
ProShares Hedge Replication ETF 0.00207 5.92 1.47892
Avantis U.S. Equity ETF 0.00145 23.04 1.59151
Avantis U.S. Small Cap Value ETF 0.00122 29.3 2.3212
Dimensional U.S. Targeted Value ETF 0.00098 26.01 1.93487
Dimensional US Core Equity Market ETF 0.00096 30.98 1.40618
iShares Russell 3000 ETF 0.00074 24.83 1.43482
Schwab U.S. Broad Market ETF 0.00046 24.86 1.43354
Dimensional U.S. Equity ETF 0.00027 31.53 1.3557
Dimensional U.S. Core Equity 2 ETF 0.00003 30.76 1.47098
Vanguard Russell 3000 ETF 0 31.87 1.43817



Head Job title Payment Year of birth
Mr. Dipal Doshi CEO & Director 968.21k 1976 (49 years)
Mr. Nathan J. Dowden President & COO 694.3k 1971 (54 years)
Dr. Natarajan Sethuraman Ph.D. Chief Scientific Officer 694.3k 1962 (63 years)
Mr. Kory James Wentworth CPA CFO & Treasurer N/A 1979 (46 years)
Dr. Jared Cohen J.D., Ph.D. General Counsel N/A
Ms. Kerry Robert M.S. Senior Vice President of People N/A
Ms. Karla MacDonald Chief Corporate Affairs Officer N/A
Mr. Kevin Healy Ph.D. Senior Vice President of Regulatory Affairs N/A

Address: United States, Boston. MA, 6 Tide Street - open in Google maps, open in Yandex maps
Website: https://www.entradatx.com